ICM
LYEL icon

Invenomic Capital Management’s Lyell Immunopharma LYEL Stock Holding History

Invenomic Capital Management’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-43,576
Closed -$1.94M – 175
2024
Q1 		$1.94M Buy
43,576
+6,255
+17% +$268K 0.1% 129
2023
Q4 		$1.45M Buy
+37,321
New +$1.34M 0.07% 153

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
WA
WuXi AppTec Shanghai, China $19M AUM 20.22% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Invenomic Capital Management's LYEL Position: Q2 2024 in Review

Invenomic Capital Management sold out of Lyell Immunopharma (LYEL) in Q2 2024, closing a stake of 43,576 shares — an estimated $1.94M sold.

Invenomic Capital Management first reported a position in LYEL in Q4 2023 and held it in 2 quarters. The position peaked at $1.94M in Q1 2024. 120 funds tracked by Wall St. Rank hold LYEL as of Q2 2024.

  • Invenomic Capital Management reported no remaining Lyell Immunopharma position as of Q2 2024 after selling out during the quarter.
  • Invenomic Capital Management sold 43,576 Lyell Immunopharma shares in Q2 2024, an estimated $1.94M.
  • Invenomic Capital Management first reported a position in Lyell Immunopharma in Q4 2023 and held it in 2 quarters.
  • Invenomic Capital Management's Lyell Immunopharma position peaked at $1.94M in Q1 2024.
  • 120 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2024.

Based on Invenomic Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.